Andrew Schorr interviews Dr. Jeff Sharman, medical director of hematology research at The US Oncology Network, exploring the multitude of new and developing therapies for the treatment of CLL. Dr. Sharman provides an update about where we stand with recent approvals and emerging approaches--including monoclonal antibodies, combination therapies and BTK (Bruton's tyrosine kinase) inhibitors--and how these advances could impact survival.
patientpower.info/video/the...
Neil
Combination therapy for our CLL
